Hillstream BioPharma signs ABSI license for ErbB2/ErbB3; appoints Sireesh Appajosyula as COO

Canton Strategic Holdings, Inc.

Licensed exclusive rights from ABSI to develop antibodies targeting ErbB2 (Her2) and ErbB3 in all human/animal diseases worldwide.
Will issue $250k in common stock to ABSI within 30 days; milestones up to $8.25M; royalties low-to-mid single digits on net sales.
Appointed director Sireesh Appajosyula as COO effective July 6, 2023; base salary $400k, annual bonus target 50% of base.
Amended CEO Randy Milby's employment: base $500k, bonus target 60%, severance period increased to 18 months on certain terminations.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sireesh Appajosyula

Chief Operating Officer

CNTN · Canton Strategic Holdings, Inc.

Effective: 2023-07-06
Filed: July 11, 2023, 7:59 PM ET

On July 6, 2023, the Board appointed Sireesh Appajosyula, the Company’s director, as Chief Operating Officer of the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sireesh Appajosyula was appointed as Chief Operating Officer at Canton Strategic Holdings, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On July 6, 2023, the Board appointed Sireesh Appajosyula, the Company’s director, as Chief Operating Officer of the Company effective immediately.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Canton Strategic Holdings, Inc. entered into ABSI Agreement with Applied Biomedical Science Institute (ABSI) valued at $250,000 (effective 2023-07-05).

Action: entry
Agreement: collaboration
Counterparty: Applied Biomedical Science Institute (ABSI)
Value: $250,000
Effective: 2023-07-05

Exact text from the filing

On July 5, 2023 (the “ABSI Effective Date”), Hillstream BioPharma, Inc. (the “Company”) entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with Applied Biomedical Science Institute (“ABSI”) pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-024270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.